Yoshito Komatsu

576 total citations
24 papers, 422 citations indexed

About

Yoshito Komatsu is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yoshito Komatsu has authored 24 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Gastroenterology, 21 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Yoshito Komatsu's work include Gastrointestinal Tumor Research and Treatment (22 papers), Gastric Cancer Management and Outcomes (15 papers) and Gastrointestinal disorders and treatments (6 papers). Yoshito Komatsu is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (22 papers), Gastric Cancer Management and Outcomes (15 papers) and Gastrointestinal disorders and treatments (6 papers). Yoshito Komatsu collaborates with scholars based in Japan, United States and Germany. Yoshito Komatsu's co-authors include Toshirou Nishida, Toshihiko Doi, Akira Sawaki, Tsuyoshi Takahashi, Tatsuo Kanda, Yukinori Kurokawa, Atsushi Ohtsu, Yoichi Naito, Kuniaki Shirao and Yasuhide Yamada and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Yoshito Komatsu

23 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yoshito Komatsu Japan	11	271	264	113	98	95	24	422
Thomas Van Looy Belgium	10	201 0.7×	233 0.9×	59 0.5×	95 1.0×	85 0.9×	19	352
Yemarshet K. Gebreyohannes Belgium	11	131 0.5×	185 0.7×	46 0.4×	86 0.9×	66 0.7×	22	322
Jung Shin Lee South Korea	10	49 0.2×	321 1.2×	64 0.6×	73 0.7×	17 0.2×	18	477
Keiichi Akahoshi Japan	12	21 0.1×	101 0.4×	99 0.9×	139 1.4×	50 0.5×	49	445
Hideki Ushiku Japan	15	55 0.2×	191 0.7×	151 1.3×	228 2.3×	8 0.1×	39	478
Elizabeth Hall–Meyers United States	5	56 0.2×	54 0.2×	24 0.2×	133 1.4×	19 0.2×	6	313
Ji Hyun Park South Korea	8	35 0.1×	146 0.6×	60 0.5×	62 0.6×	43 0.5×	22	307
Ting‐Jung Wu Taiwan	11	50 0.2×	69 0.3×	113 1.0×	82 0.8×	4 0.0×	21	359
Sabina Murgioni Italy	11	52 0.2×	145 0.5×	85 0.8×	73 0.7×	10 0.1×	38	361
Young Jin Kim South Korea	12	43 0.2×	172 0.7×	201 1.8×	61 0.6×	9 0.1×	24	437

Countries citing papers authored by Yoshito Komatsu

Since Specialization

Citations

This map shows the geographic impact of Yoshito Komatsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshito Komatsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshito Komatsu more than expected).

Fields of papers citing papers by Yoshito Komatsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshito Komatsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshito Komatsu. The network helps show where Yoshito Komatsu may publish in the future.

Co-authorship network of co-authors of Yoshito Komatsu

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshito Komatsu. A scholar is included among the top collaborators of Yoshito Komatsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshito Komatsu. Yoshito Komatsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotani, Daisuke, Takayuki Yoshino, Toshiki Masuishi, et al.. (2025). Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. 30(10). 2043–2052.

Bando, Hideaki, Jun Watanabe, Yusuke Suwa, et al.. (2025). Clinical validation of plasma circulating-tumor DNA assay using highly sensitive Safe-SeqS technology for detecting RAS and BRAF V600E in metastatic colorectal cancer.. Journal of Clinical Oncology. 43(4_suppl). 50–50. 1 indexed citations

Hirota, Seiichi, Ukihide Tateishi, Yuji Nakamoto, et al.. (2024). English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 29(6). 647–680. 13 indexed citations

Naito, Yoichi, Yoshito Komatsu, Yukinori Kurokawa, et al.. (2023). 1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Annals of Oncology. 34. S1031–S1032. 1 indexed citations

Gotohda, Naoto, Toshirou Nishida, Shinsuke Sato, et al.. (2023). Re‐appraisal of the universal definition of tumor rupture among patients with high‐risk gastrointestinal stromal tumors. Annals of Gastroenterological Surgery. 7(6). 1021–1031. 4 indexed citations

Sawaki, Akira, Yukinori Kurokawa, Yoshitaka Honma, et al.. (2022). PS4-3 A phase III trial of pimitespib (TAS-116) in patients with advanced gastrointestinal stromal tumor: CHAPTER-GIST-301. Annals of Oncology. 33. S467–S467. 3 indexed citations

Kurokawa, Yukinori, Yoshitaka Honma, Akira Sawaki, et al.. (2022). Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 33(9). 959–967. 73 indexed citations

Nishida, Toshirou, Shinsuke Sato, Masato Ozaka, et al.. (2022). Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world. Gastric Cancer. 25(5). 956–965. 13 indexed citations

Takahashi, Tsuyoshi, Toshirou Nishida, Toshihiro Kudo, et al.. (2020). Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 38(4_suppl). 823–823. 2 indexed citations

10.

Doi, Toshihiko, Yukinori Kurokawa, Akira Sawaki, et al.. (2019). Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. European Journal of Cancer. 121. 29–39. 46 indexed citations

11.

Naito, Yoichi, Toshihiko Doi, Tsuyoshi Takahashi, et al.. (2019). Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study. Annals of Oncology. 30. vi88–vi88. 1 indexed citations

12.

Komatsu, Yoshito, Toshihiko Doi, Akira Sawaki, et al.. (2015). Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology. 20(5). 905–912. 26 indexed citations

13.

Komatsu, Yoshito, et al.. (2015). Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Japanese Journal of Clinical Oncology. 45(11). 1016–1022. 10 indexed citations

14.

Kang, Yoon‐Koo, Jianmin Xu, Yoshito Komatsu, et al.. (2013). Subgroup Analysis of Asian Patients in the Phase III Trial (GRID) of Regorafenib in Pretreated Metastatic GIST. Annals of Oncology. 24. ix6–ix6. 1 indexed citations

15.

Sawaki, Akira, Toshirou Nishida, Toshihiko Doi, et al.. (2011). Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor. Cancer. 117(20). 4633–4641. 68 indexed citations

16.

Kanda, Tatsuo, Toshirou Nishida, Norihito Wada, et al.. (2011). Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. International Journal of Clinical Oncology. 18(1). 38–45. 21 indexed citations

17.

Agata, Naoki, et al.. (2011). Interim safety results from the all cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 29(15_suppl). e15133–e15133. 1 indexed citations

18.

Shirao, Kuniaki, Toshirou Nishida, Toshihiko Doi, et al.. (2009). Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Investigational New Drugs. 28(6). 866–875. 55 indexed citations

19.

Nishida, Toshirou, Tsuyoshi Takahashi, Akiko Nishitani, et al.. (2009). Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. International Journal of Clinical Oncology. 14(2). 143–149. 50 indexed citations

20.

Sawaki, Akira, Yasuhide Yamada, Yoshito Komatsu, et al.. (2009). Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemotherapy and Pharmacology. 65(5). 961–967. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact